Scarica l'app Stockscreener
90.04
1.74%
1.54
Dopo l'orario di chiusura:
90.60
0.56
+0.62%
Precedente Chiudi:
$88.50
Aprire:
$89.24
Volume 24 ore:
3.45M
Relative Volume:
1.12
Capitalizzazione di mercato:
$11.73B
Reddito:
$638.78M
Utile/perdita netta:
$-22.66M
Rapporto P/E:
-516.28
EPS:
-0.1744
Flusso di cassa netto:
$122.18M
1 W Prestazione:
+11.57%
1M Prestazione:
+46.31%
6M Prestazione:
+362.22%
1 anno Prestazione:
+694.00%
Intervallo 1D:
$87.29
$91.99
Intervallo di 1 settimana:
$74.60
$91.99
Portata 52W:
$11.16
$91.99
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HNGE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
90.04 | 11.17B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
278.57 | 45.44B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
82.58 | 15.43B | 1.36B | -302.91M | -219.93M | -1.7182 |
BTSG
Brightspring Health Services Inc
|
55.69 | 11.20B | 13.65B | 169.86M | 412.12M | 1.0758 |
HNGE
Hinge Health Inc
|
95.21 | 7.71B | 646.34M | -512.40M | 202.76M | -6.6871 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Iniziato | Piper Sandler | Neutral |
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
10x Genomics (TXG) Stock Could Look Pricey Against Its Current Sales Base - simplywall.st
Director Shehnaaz Suliman Sells 5,723 Shares of 10x Genomics Inc (TXG) - gurufocus.com
10x Genomics Inc (TXG) Stock Up 11.2% but GF Value Says Overvalued -- GF Score: 60/100 - gurufocus.com
10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com India
10x genomics director Shehnaaz Suliman sells $464,667 in stock - Investing.com
Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com Nigeria
Form 4 10X Genomics Inc For: 24 September - Investing.com India
Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions. - Stock Titan
TXG Stock Rallies As AI Deal And Legal Win Shift Outlook - StocksToTrade
At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan. - Stock Titan
10X Genomics Inc stock hits 52-week high at 82.76 USD - Investing.com
10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance UK
TXG Stock Rallies As AI, Legal Wins Shift Outlook - StocksToTrade
10X Genomics Inc Stock (TXG) Moved Up by 7.42% on Sep 24: What Signal Does It Send? - TradingKey
10x Genomics Inc (1KJ.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
10x Genomics, Inc. (TXG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Precision Trading with 10x Genomics Inc. (TXG) Risk Zones - Stock Traders Daily
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know - Yahoo Finance
Form 144 10X Genomics For: 22 September By Investing.com - Investing.com Canada
5,723 10x Genomics (NASDAQ: TXG) shares set for Rule 144 sale - Stock Titan
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - Benzinga
Price to earnings forward of 10x Genomics Inc Class A – LS:A2PPQJ - TradingView
10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors - gurufocus.com
10x Genomics (TXG) Institutional Ownership 2026 $TXG - MarketBeat
10x Genomics (TXG) Stock May Look Pricey As Oncology AI News Lands - Yahoo Finance
10x Genomics stock hits 52-week high at 78.0 USD - Investing.com
10x Genomics Inc (TXG) Stock Up 6.0% but GF Value Says Overvalued -- GF Score: 56/100 - GuruFocus
4 Best Genetic Sequencing Stocks for 2026 and How to Invest - fool.com
Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance
10x Genomics (TXG) CFO Adam Taich Sells 46,388 Shares - GuruFocus
10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com Nigeria
10x Genomics (TXG) CFO sells shares under preset trading plan - Stock Titan
10x Genomics to Use Lunit’s AI-Powered Pathology Platform for Oncology Biomarker Discovery - GenomeWeb
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research - PR Newswire
10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com - Investing.com Australia
symbol__ Stock Quote Price and Forecast - CNN
10x Genomics (NASDAQ: TXG) executive plans multimillion-dollar stock sale - Stock Titan
10x Genomics Insider John R. Stuelpnagel Sells 20,000 Shares Between $60.66 and $62.61 on September 3, 2026 (NASDAQ: TXG) - Kalkine Media
10x Genomics stock hits 52-week high at 66.95 USD By Investing.com - Investing.com South Africa
Macrogen to offer 10x Genomics spatial biology platform in Asia first - Korea Biomedical Review
10x genomics director Stuelpnagel sells $1.2 million in shares - investing.com
10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100 - GuruFocus
10x Genomics (TXG) director offloads 20,000 shares in open-market trades - Stock Titan
T. Rowe Price reports 10%+ holding in 10x Genomics (TXG) - Stock Titan
Stifel reiterates Buy rating on 10X Genomics stock By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on 10X Genomics stock - investing.com
10X Genomics Inc (TXG) Key Financial Ratios – Valuation, Profitability & More - Value Research
10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift - Stock Titan
Founder trust at 10x Genomics (NASDAQ: TXG) moves to sell 20,000 shares - Stock Titan
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - finance.yahoo.com
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10 X Genomics Inc Azioni (TXG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Sep 22 '26 |
Sale |
81.22 |
25,000 |
2,030,562 |
1,050,249 |
1.50%
2.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):